ADCT — ADC Therapeutics S.A.

ADC Therapeutics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Revenues: $20.0 million for Q1 2026, up from $17.4 million in Q1 2025, reflecting a 15% year-over-year growth.
• Licensing Revenues: Decreased due to a $5 million milestone received in the prior year.
• Cost of Product Sales: Increased by $1.6 million to $3.6 million, attributed to a shift in personnel costs from R&D to commercial manufacturing.
• Total Operating Expenses: Reported at $46.1 million; adjusted operating expenses were $42.9 million, down 13% year-over-year due to reduced R&D expenses.
• Net Loss: GAAP net loss of $33 million ($0.21 per share), improved from a loss of $38.6 million ($0.36 per share) in Q1 2025. Non-GAAP adjusted net loss was $19.7 million, compared to $24 million in the prior year.
• Cash Position: Ended Q1 2026 with $231 million in cash, providing a runway into 2028.

2. Strategic Updates and Business Highlights

• ZYNLONTA: Positioned as a differentiated treatment for third-line plus DLBCL patients. The company is focused on expanding ZYNLONTA's use into earlier treatment lines and indolent lymphomas.
• Upcoming Trials: Anticipating top-line data from the LOTIS-5 trial in Q2 2026, which could significantly impact ZYNLONTA's market potential.
• Enrollment: LOTIS-7 trial expected to complete enrollment of approximately 100 patients in Q2 2026, with full data anticipated by year-end.
• Market Potential: ZYNLONTA has the potential to achieve peak annual revenues of $600 million to $1 billion in the U.S. with successful regulatory approvals and compendia listings.

3. Forward Guidance and Outlook

• LOTIS-5 Data: Expected to be shared by the end of June 2026, with a supplemental biologics license application (sBLA) planned for submission by year-end if results are positive.
• Revenue Growth: Anticipated acceleration in revenue growth starting in 2027, contingent on positive trial outcomes and subsequent approvals.
• Regulatory Strategy: Plans for compendia inclusion and regulatory assessments for indolent lymphomas based on upcoming trial data.

4. Bad News, Challenges, or Points of Concern

• Competitive Environment: Despite a stable revenue performance, the company noted ongoing competitive pressures in the market.
• Variability in Sales: While Q1 showed growth, the company emphasized that quarter-to-quarter variability in customer orders makes it difficult to establish a definitive trend.
• Cost of Goods: The shift in personnel costs to cost of goods is expected to inflate COGS in future quarters, which could impact profitability.

5. Notable Q&A Insights

• Data Blinding: The CEO confirmed that the data for LOTIS-5 remains blinded, with no current insights available until the database is locked.
• Top-Line Data Disclosure: The company plans to disclose relevant information on primary endpoints, including median progression-free survival (PFS) and safety data, during the top-line announcement.
• Market Impact of LOTIS-5: Ameet Mallik indicated that even with a positive LOTIS-5 readout, immediate revenue impacts are not expected until regulatory approvals are secured, likely in 2027.
• Investor Engagement: The company is currently in a quiet period regarding investor engagement until the LOTIS-5 data is disclosed.

This summary encapsulates the key points from ADC Therapeutics' Q1 2026 earnings call, highlighting financial performance, strategic initiatives, future outlook, and areas of concern.